Spain Gene Editing Market (2024-2029)
The Spain Gene Editing Market was valued at $25.7 Million in 2024 and projected to reach to $40.3 Million by 2029, representing a compound annual growth rate of 9.4%. Spain's gene editing market is poised for sustained expansion as the country strengthens its biotechnology ecosystem and healthcare infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Spain Gene Editing Market Trends and Insights
- This expansion reflects Spain's strengthening position in European biotechnology and increasing investment in precision medicine infrastructure.
- Spain is leveraging its research capabilities and healthcare system modernization to advance gene editing applications across therapeutic and diagnostic domains. The Spanish market benefits from supportive regulatory frameworks and collaborative research initiatives within Europe's broader gene editing ecosystem.
- Spain's pharmaceutical and biotech sectors are increasingly adopting CRISPR and alternative gene-editing technologies to address unmet clinical needs.
- By 2029, Spain is expected to capture a larger share of European gene editing innovation, driven by academic partnerships, government funding, and private sector investment in genomic medicine..
Key Market Statistics
- CAGR (2024-2029) 9.4% CAGR
- Market Size, 2024 ~USD 25.7 Million
- Forecast, 2029 ~USD 40.3 Million
- Country Spain
Spain Gene Editing Market Overview
Market Valuation Growth :
Spain's gene editing market is valued at $25.7 million in 2024, with a projected CAGR of 9.4% through 2029, reaching $40.3 million by forecast end, demonstrating strong regional momentum.
European Biotechnology Hub :
Spain is establishing itself as a key player in European gene editing innovation, supported by robust research institutions, government funding initiatives, and strategic partnerships with leading biotech firms.
Precision Medicine Infrastructure :
Spain's healthcare system modernization and increased investment in precision medicine are creating favorable conditions for gene editing adoption across therapeutic applications and clinical research.
Research Capability Expansion :
Spanish research institutions are advancing gene editing technologies and clinical applications, positioning the country as an attractive market for biotech companies and investment in cutting-edge therapeutic solutions.
Spain Gene Editing Market Dynamics
- With a 9.4% CAGR through 2029, the market reflects growing adoption of precision medicine and increased R&D investments in gene therapy applications.
- Spanish healthcare providers and research institutions are increasingly integrating gene editing technologies into clinical practice, supported by favorable regulatory frameworks and EU funding mechanisms. The outlook for Spain remains optimistic, driven by collaborations between academic institutions and private biotech companies, rising patient awareness of genetic therapies, and government initiatives promoting life sciences innovation.
- As Spain continues to position itself within the broader European biotech landscape, opportunities for market expansion in rare genetic diseases, oncology, and inherited disorders are expected to accelerate investment and clinical adoption through 2029..
Related Ecosystem
Key Takeaways
- Spain's gene editing market is valued at $25.7 million in 2024 and is forecast to reach $40.3 million by 2029, representing a 9.4% CAGR.
- Spain is strengthening its position as a European hub for gene editing research and development through academic-industry collaboration.
- Regulatory support and healthcare modernization in Spain are accelerating adoption of CRISPR and alternative gene-editing technologies.
- Spain's market growth is driven by increasing investment in precision medicine and genomic research infrastructure through 2029.
Gene Editing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | CROS & CDMOS (End User) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 10.2% from 2024 to 2029 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 4.67 (2024) |
| Revenue Forecast (Billions) | ~USD 7.59 (2029) |
| Segments Covered | Offering, Type, Technique, Technology, Application, End User |
Spain Gene Editing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Cell Line Development & Engineering
- Gene Editing Kits
- Gene Editing Libraries
- Gene Editing Reagents
- Grna Synthesis & Vector Construction
- Library Construction & Screening
- Other Services
- Reagents & Consumables
- Software & Systems
By Technique
- Gene Silencing
- Knock-In
- Knock-Out
- Other Techniques
By Technology
- Antisense
- Base Editing
- Crispr
- Other Technologies
- Rnai
- Talens
- Zfns
By Application
- Cell Line Engineering
- Drug Discovery & Development
- Genome Editing
- Other Applications
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Other End Users
- Pharmaceutical & Biotechnology Companies
SPAIN: GENE EDITING SERVICES MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 7.8 | 7.3 | 7.9 | 8.7 | 9.6 | 10.6 | 11.7 | 12.9 | 10.2 |
| CROS & CDMOS | 1.6 | 1.6 | 1.8 | 2.1 | 2.4 | 2.7 | 3.1 | 3.5 | 14.3 |
| OTHER END USERS | 4.5 | 4 | 4.2 | 4.5 | 4.8 | 5.1 | 5.4 | 5.7 | 6.2 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 11.8 | 11 | 11.8 | 12.9 | 14 | 15.3 | 16.7 | 18.2 | 9.1 |
| TOTAL | 25.7 | 23.9 | 25.7 | 28.2 | 30.8 | 33.7 | 36.9 | 40.3 | 9.4 |
SPAIN: GENE EDITING PRODUCTS MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 18.1 | 16.9 | 17 | 18.2 | 19.5 | 20.8 | 22.2 | 23.7 | 6.9 |
| CROS & CDMOS | 8.4 | 7.9 | 8.1 | 8.9 | 9.6 | 10.5 | 11.3 | 12.3 | 8.6 |
| OTHER END USERS | 7.9 | 7.1 | 6.9 | 7.1 | 7.3 | 7.6 | 7.8 | 8 | 2.9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 25.5 | 23.5 | 23.5 | 24.9 | 26.4 | 27.9 | 29.5 | 31.2 | 5.8 |
| TOTAL | 59.8 | 55.4 | 55.6 | 59.1 | 62.9 | 66.7 | 70.8 | 75.2 | 6.2 |
Target Audience
- Biotech & Pharmaceutical Companies : Strategic decision-makers seeking to expand gene editing portfolios in Spain need market sizing, competitive intelligence, and regulatory pathways to guide market entry and investment decisions.
- Healthcare Providers & Hospitals : Spanish hospital networks and healthcare systems require insights into gene editing adoption trends, clinical applications, and reimbursement models to plan precision medicine service offerings.
- Research Institutions & Universities : Academic researchers and biotech incubators need market data to identify funding opportunities, commercialization pathways, and collaboration potential with industry partners in Spain.
- Investment & Venture Capital Firms : Investors evaluating biotech opportunities in Spain require detailed market analysis, growth projections, and competitive landscape data to assess portfolio companies and funding decisions.
- Government & Policy Makers : Spanish health authorities and innovation agencies need market intelligence to inform healthcare policy, research funding priorities, and precision medicine infrastructure development strategies.
Key Companies in the Spain Gene Editing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| EPPENDORF AG | Germany | Private Company | Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors), |
| ILLUMINA INC | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| CALYXT | United States | Public Company | RTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects, |
| MAXCYTE, INC | United States | Public Company | ExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables, |
| BECKMAN COULTER | United States | Private Company | Clinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments, |
| TAKEDA PHARMACEUTICAL COMPANY | Japan | Public Company | Gastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables), |
| REVVITY, INC. | United States | Public Company | Diagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment), |
| GENSCRIPT | Hong Kong | Public Company | Life Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| LONZA | Switzerland | Public Company | Integrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| SANGAMO THERAPEUTICS | United States | Public Company | Hemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant), |
| PRECISION BIOSCIENCES | United States | Public Company | ARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243), |
| CELLECTIS S.A. | France | Public Company | Allogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue, |
| REGENERON PHARMACEUTICALS, INC. | United States | Public Company | EYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics), |
| TAKARA BIO INC. | Japan | Private Company | Genetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related), |
EPPENDORF AG
Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.
ILLUMINA INC
Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.
CALYXT
Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.
MAXCYTE, INC
MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.
BECKMAN COULTER
Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.
TAKEDA PHARMACEUTICAL COMPANY
Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.
DANAHER CORPORATION
Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.
REVVITY, INC.
Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.
MERCK KGAA
Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.
GENSCRIPT
GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.
LONZA
Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.
SANGAMO THERAPEUTICS
Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.
PRECISION BIOSCIENCES
Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.
CELLECTIS S.A.
Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.
REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.
TAKARA BIO INC.
Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.
Reasons to Buy this Report
- Market-Specific Growth Projections : Access detailed forecasts for Spain's gene editing market through 2029, including segment breakdowns, application areas, and regional growth drivers specific to the Spanish healthcare landscape.
- Competitive Landscape Analysis : Identify key players, emerging biotech companies, and research institutions operating in Spain's gene editing sector, with insights into market positioning and strategic initiatives.
- Regulatory & Reimbursement Insights : Understand Spain's regulatory framework for gene editing therapies, reimbursement policies, and healthcare system dynamics that influence market adoption and commercialization strategies.
- Investment & Partnership Opportunities : Discover funding trends, venture capital activity, and collaboration opportunities between Spanish institutions and international biotech firms driving market expansion.
- Clinical Application Trends : Analyze which therapeutic areas and genetic conditions are driving gene editing adoption in Spain, including rare diseases, oncology, and inherited disorders with highest growth potential.
Frequently asked questions
What is the current size of Spain's gene editing market?
Spain's gene editing market was valued at $25.7 million in 2024 and is projected to grow to $40.3 million by 2029.
What is the expected growth rate for Spain's gene editing market?
Spain's gene editing market is expected to grow at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2029.
What factors are driving growth in Spain's gene editing market?
Spain's market growth is driven by increased investment in precision medicine, supportive regulatory frameworks, academic-industry partnerships, and adoption of CRISPR technologies in therapeutic applications.
How does Spain's gene editing market compare to other European markets?
Spain is establishing itself as a significant player in European gene editing, with growing research capabilities and healthcare infrastructure supporting innovation in genomic medicine.
What gene editing technologies are most prevalent in Spain?
CRISPR-based technologies dominate Spain's gene editing landscape, alongside emerging alternative platforms being adopted by Spanish biotech and pharmaceutical companies.
RESEARCH METHODOLOGY
This study on the gene editing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the gene editing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources, such as the International Chromosome and Genome Society (ICGS), the National Human Genome Research Institute (NHGRI), the Asia Pacific Society of Human Genetics (APSHG), the Genetics Society of America (GSA), the European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Centre for Cellular & Molecular Biology (CCMB) (India), and the Department of Biotechnology (DBT) (India). Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global gene editing market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global gene editing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing gene editing products and services; experts from the demand side, such as personnel from pharmaceutical & biotechnology companies, Academic & research institutes, and CROs & CDMOs. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the gene editing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the gene editing market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Top-down Approach
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
The gene editing market, as covered within the scope of this report, includes products, technologies, and services that facilitate genetic modifications across various applications. This encompasses reagents and consumables, as well as software and systems for planning, executing, and analyzing gene editing processes. Additionally, the report covers services that utilize gene editing technologies like CRISPR, TALEN, ZFN, and other methods such as Meganucleases, PiggyBac, and Prime Editing, applied in areas like cell line engineering, genome editing, drug discovery, clinical diagnostics, and xenotransplantation. These components serve end users, including pharmaceutical and biotechnology companies involved in therapeutic development, as well as academic and research institutes focused on scientific research.
Stakeholders
- Manufacturers and distributors of gene editing products and services
- Pharmaceutical and biotechnology companies
- Market research and consulting firms
- R&D centers
- Researchers and scientists
- Academic & research institutes
- CDMOs & CROs
- Biobanks
- Diagnostic companies.
Report Objectives
- To define, describe, segment, and forecast the gene editing market based on offerings, product type, product application, product technology, reagent & consumables technique, product end user, service type, service application, service end user and region
- To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall gene editing market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments concerning six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
- To strategically profile the key players in the global gene editing market and comprehensively analyze their core competencies2 and market rankings.
- To track and analyze competitive developments, such as product launches, acquisitions, collaborations, expansions, and partnerships in the gene editing market.
- To profile the key players in the global gene editing market and comprehensively analyze their instruments, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the gene editing market
- To benchmark players within the gene editing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Get the Full Gene Editing Market Report
Full forecast, segment splits, and company analysis for all Gene Editing Market.
- US Gene Editing Market
- Canada Gene Editing Market
- Germany Gene Editing Market
- France Gene Editing Market
- UK Gene Editing Market
- Italy Gene Editing Market
- China Gene Editing Market
- Japan Gene Editing Market
- India Gene Editing Market
- South Korea Gene Editing Market
- Australia Gene Editing Market
- Brazil Gene Editing Market
- United Arab Emirates Gene Editing Market
- Rest Of Europe Gene Editing Market
- Rest Of Asia Pacific Gene Editing Market
- Rest Of Latin America Gene Editing Market
- Ksa Gene Editing Market
- Other GCC Countries Gene Editing Market
- UAE Gene Editing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
